IRON

IRON

USD

Disc Medicine Inc. Common Stock

$86.060+3.050 (3.674%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$83.010

Haut

$87.125

Bas

$83.010

Volume

0.64M

Fondamentaux de l'Entreprise

Capitalisation Boursière

3.2B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.43M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $30.82Actuel $86.060Haut $95.95

Actualités Connexes

GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Voir plus
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Analyst Upgrades

Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target

Stifel analyst Stephen Willey reinstates Disc Medicine with a Buy and announces $125 price target.

Voir plus
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Voir plus
Disc Medicine to Participate in Upcoming Investor Conferences
Analyst Upgrades

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine with a Overweight and raises the price target from $90 to $115.

Voir plus
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.